Attenuation of inducible Th2 immunity with autoimmune disease progression.

Antigen-based therapy for the treatment of type 1 diabetes. Diabetes (2009) 0.93

The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A (2001) 0.87

Transgenically induced GAD tolerance curtails the development of early beta-cell autoreactivities but causes the subsequent development of supernormal autoreactivities to other beta-cell antigens. Diabetes (2009) 0.83

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49

Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35

Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest (1994) 2.28

Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci (1994) 2.24

Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med (1996) 2.06

Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A (1992) 1.93

Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol (2001) 1.89

Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein. J Neurosci (1987) 1.78

Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet (1992) 1.73

Brain glutamate decarboxylase cloned in lambda gt-11: fusion protein produces gamma-aminobutyric acid. Science (1986) 1.60

GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol (1999) 1.28

Cryptosporidiosis in tourists returning from the Caribbean. N Engl J Med (1985) 1.27

Permanent diabetes without serological evidence of autoimmunity after transient neonatal diabetes. Diabetes Care (1992) 1.08

Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med (1997) 1.04

Cloning and sequence analysis of a murine cDNA encoding glutamate decarboxylase (GAD65). Biochim Biophys Acta (1993) 1.03

In situ hybridization to localize mRNA encoding the neurotransmitter synthetic enzyme glutamate decarboxylase in mouse cerebellum. Proc Natl Acad Sci U S A (1986) 1.03

T cell cross-reactivity between coxsackievirus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med (1994) 1.00

The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol (2001) 1.00

Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest (1993) 0.97

Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol Rev (1998) 0.95

Horizontal cells in cat and monkey retina express different isoforms of glutamic acid decarboxylase. Vis Neurosci (1994) 0.90

Splicing defect at the ornithine aminotransferase (OAT) locus in gyrate atrophy. Am J Hum Genet (1990) 0.83

Antigen-based immunotherapy for autoimmune disease: from animal models to humans? Immunol Today (1999) 0.81

Glutamate decarboxylase: an autoantigen in IDDM. Diabetes Care (1992) 0.80

Insulin selectively primes Th2 responses and induces regulatory tolerance to insulin in pre-diabetic mice. Diabetologia (1998) 0.79

The postnatal maternal environment influences diabetes development in nonobese diabetic mice. J Autoimmun (2007) 0.79

Distribution of glutamic acid decarboxylase (Mr 67,000) in the basal ganglia of the rat: an immunohistochemical study with a selective cDNA-generated polyclonal antibody. J Neurocytol (1991) 0.77

Alternative forms of GAD and GABAA receptors. Adv Biochem Psychopharmacol (1992) 0.76

In vivo administration of c-Fos antisense oligonucleotides accelerates amygdala kindling. Neurosci Lett (1998) 0.75

Permanent diabetes developing after transient neonatal diabetes. Lancet (1993) 0.75

Pneumocystis carinii pneumonia. Adv Exp Med Biol (1986) 0.75

Antisense oligonucleotides to C-fos reduce postictal seizure susceptibility following fully kindled seizures in rats. Neurosci Lett (1999) 0.75